Compare Iron Mountain Inc (IRM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Iron Mountain Inc trades at $111 (market cap $34.12B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Iron Mountain Inc is far larger — about 7× Travere Therapeutics Inc. Common Stock's market cap, and Iron Mountain Inc pays a 3.02% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| IRM | TVTX | |
|---|---|---|
Market Cap | $34.12B | $4.88B |
Volume | 1,143,756 | 1,668,577 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $67.52 |
52-Week Low | $78.86 | $26.79 |
Typical Hold Time | 80 Days | 0 Days |
Enterprise Value | $53.53B | $5.01B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $110.86, down 3.68% on the day, amid a neutral technical signal. The company shows steady revenue growth, with 2025 revenue at $6.90B and a net income margin of 5.54%, though profitability has been volatile. Recent news highlights expansion in data centers and digital solutions, with a 300MW pipeline target. Analyst consensus is bullish with a $142.75 price target, but high debt levels and negative shareholder equity pose fundamental concerns.
The outlook for IRM is mixed; growth in digital and data center services offers upside, supported by strong analyst buy ratings. However, elevated valuation multiples, significant debt burden, and inconsistent earnings present risks. Investors should weigh the growth potential against financial leverage and margin pressures when considering a position.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
